CHRS Coherus BioSciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CHRS

Price (delayed)

$6.105

Market cap

$486.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.76

Enterprise value

$898.57M

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings ...

Highlights
The gross profit has contracted by 48% YoY and by 18% from the previous quarter
The equity has contracted by 41% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.coherus.com/
Peers: AGEN AMGN RGEN ACOR

Key stats

What are the main financial stats of CHRS
Market
Shares outstanding
79.61M
Market cap
$486.02M
Enterprise value
$898.57M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.26
Earnings
Revenue
$211.04M
EBIT
-$259.28M
EBITDA
-$255.58M
Free cash flow
-$243.16M
Per share
EPS
-$3.76
Free cash flow per share
-$3.13
Book value per share
-$1.77
Revenue per share
$2.72
TBVPS
$6.12
Balance sheet
Total assets
$480.85M
Total liabilities
$618.27M
Debt
$476.1M
Equity
-$137.42M
Working capital
$242.54M
Liquidity
Debt to equity
-3.46
Current ratio
2.75
Quick ratio
2.17
Net debt/EBITDA
-1.61
Margins
EBITDA margin
-121.1%
Gross margin
66.8%
Net margin
-138.2%
Operating margin
-121.7%
Efficiency
Return on assets
-53.8%
Return on equity
N/A
Return on invested capital
-43.1%
Return on capital employed
-75.8%
Return on sales
-122.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CHRS stock price

How has the Coherus BioSciences stock price performed over time
Intraday
0.08%
1 week
-4.46%
1 month
-17.72%
1 year
-50.88%
YTD
-22.92%
QTD
-22.92%

Financial performance

How have Coherus BioSciences's revenue and profit performed over time
Revenue
$211.04M
Gross profit
$140.96M
Operating income
-$256.88M
Net income
-$291.75M
Gross margin
66.8%
Net margin
-138.2%
The net margin has dropped by 57% year-on-year and by 19% since the previous quarter
The company's operating margin has shrunk by 51% YoY and by 19% QoQ
The gross profit has contracted by 48% YoY and by 18% from the previous quarter
The revenue has declined by 35% year-on-year and by 12% since the previous quarter

Growth

What is Coherus BioSciences's growth rate over time

Valuation

What is Coherus BioSciences stock price valuation
P/E
N/A
P/B
N/A
P/S
2.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.26
Coherus BioSciences's EPS has decreased by 4.7% QoQ
The equity has contracted by 41% from the previous quarter
The P/S is 93% below the 5-year quarterly average of 32.8 and 20% below the last 4 quarters average of 2.8
The revenue has declined by 35% year-on-year and by 12% since the previous quarter

Efficiency

How efficient is Coherus BioSciences business performance
Coherus BioSciences's return on sales has shrunk by 52% YoY and by 18% QoQ
The return on assets has declined by 34% year-on-year and by 14% since the previous quarter
CHRS's return on invested capital is up by 14% year-on-year and by 7% since the previous quarter

Dividends

What is CHRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CHRS.

Financial health

How did Coherus BioSciences financials performed over time
The total assets is 22% less than the total liabilities
Coherus BioSciences's quick ratio has decreased by 34% YoY
The total assets has contracted by 29% YoY and by 13% from the previous quarter
The debt to equity has plunged by 181% YoY but it has grown by 30% from the previous quarter
The equity has contracted by 41% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.